10 results
10-K
2023 FY
TSBX
Turnstone Biologics Corp
21 Mar 24
Annual report
8:51pm
for the majority of patients in our chosen solid tumor indications. Our innovative Selected TIL approach focuses on selecting and expanding the most potent tumor … oncolytic viral immunotherapies. In late 2020, we acquired an innovative TIL platform and capabilities to expand our portfolio of cancer immunotherapies
8-K
EX-99.1
TSBX
Turnstone Biologics Corp
21 Mar 24
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
5:14pm
experience in innovative immunotherapies for solid tumors, currently serves as Deputy Director of the Perlmutter Cancer Center and Co-Director
10-Q
2023 Q2
TSBX
Turnstone Biologics Corp
1 Sep 23
Quarterly report
4:39pm
that provide curative outcomes for the majority of patients in our chosen solid tumor indications. Our innovative Selected TIL approach focuses … could materially harm our business.
Our innovative Selected TIL approach focuses on selecting and manufacturing the most potent tumor reactive T cells
424B4
738eeow4ptjyb jag
21 Jul 23
Prospectus supplement with pricing info
7:14pm
S-1/A
l689m4 wo0d319n8
23 Jun 23
IPO registration (amended)
9:49pm
S-1
a2tysosp06biorrjgg
12 Jun 23
IPO registration
4:28pm
DRS
wyw184wu7xxw fgx09nc
15 May 23
Draft registration statement
12:00am
- Prev
- 1
- Next